Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the application of precision medicine in breast cancer.

Dr. Dang on the DESTINY-Breast01 Trial in HER2+ Metastatic Breast Cancer

Chau Dang, MD, discusses the evaluation of the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer in the DESTINY-Breast01 trial.

Dr. Rampal on Unmet Needs in Myelofibrosis and Polycythemia Vera

Raajit K. Rampal, MD, PhD, discusses unmet needs in the treatment of patients with myelofibrosis and polycythemia vera.

Dr. Dang on Long-Term Findings of the APHINITY Trial in HER2+ Breast Cancer

Chau Dang, MD, discusses the APHINITY trial, which explored the use of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) plus chemotherapy in patients with HER2-positive breast cancer.

Dr. Janjigian on Data With Atezolizumab/Bevacizumab Combo in HCC

Yelena Y. Janjigian, MD, discusses the improvement in efficacy and toxicity with patients with hepatocellular carcinoma who are treated with bevacizumab and atezolizumab when compared with sorafenib.

Dr. Bochner on Standardizing Molecular Profiling in Bladder Cancer

Bernard H. Bochner, MD, FACS, discusses the potential standardization of molecular profiling in bladder cancer.

Dr. Drilon on the Safety Profile of Brigatinib in ALK+ NSCLC

Alexander Drilon, MD, discusses the safety profile of brigatinib in ALK-positive non–small cell lung cancer.

Next Page >>

Inside Oncology

View more videos >>